|
| Prevalence of RLS |
Restless Legs Syndrome (RLS) is prevalent;10% of the US population report RLS symptoms in its mild, moderate, and severe forms. [2,3]
|
Risk Factors
Risk factors for developing Restless Legs Syndrome include:
- Age: RLS is primarily a condition of middle-to-older age [2,14]
- Gender: Women are slightly more likely than men to develop RLS [3,14]
There is also a strong suggestion of a familial component to this syndrome. [1,11]
|
Requip is indicated for patients with moderate-to-severe primary RLS.
Requip has been associated with sedating effects, including somnolence, and the possibility of falling asleep while engaged in activities of daily living, including operation of a motor vehicle. Syncope or symptomatic hypotension may occur, particularly during initial treatment or dose titration. Impulse control symptoms, including pathological gambling and hypersexuality, have been reported in patients treated with dopaminergic agents, including ropinirole.
For More Safety Information about Requip, click here.
Complete Prescribing Information for Requip® (ropinirole HCl) Tablets
|
This site is intended for US healthcare professionals only.
© 1997-2008 GlaxoSmithKline. All Rights Reserved.
Legal Notices | Privacy Statement | Medicine Savings | Contact Us
|
|
|
Prevalence of RLS
